UBS Group
CLYM

UBS Group’s Climb Bio CLYM Stock Holding History

UBS Group’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$589K Buy
85,945
+14,622
+21% +$84.4K ﹤0.01% 5969
2025
Q4 		$285K Sell
71,323
-334,081
-82% -$802K ﹤0.01% 6387
2025
Q3 		$815K Buy
405,404
+22,922
+6% +$42.6K ﹤0.01% 5728
2025
Q2 		$474K Buy
382,482
+257
+0.1% +$320 ﹤0.01% 6055
2025
Q1 		$466K Sell
382,225
-33,130
-8% -$53.7K ﹤0.01% 5905
2024
Q4 		$748K Buy
415,355
+399,108
+2,457% +$1.44M ﹤0.01% 5541
2024
Q3 		$82.7K Buy
16,247
+14,029
+633% +$99.2K ﹤0.01% 6484
2024
Q2 		$15.8K Sell
2,218
-3,707
-63% -$24.7K ﹤0.01% 7458
2024
Q1 		$16.2K Buy
+5,925
New +$16.3K ﹤0.01% 7013
2023
Q4 		– Sell
-89
Closed -$234 – 10009
2023
Q3 		$234 Buy
+89
New +$243 ﹤0.01% 8667
2022
Q3 		– Sell
-2,282
Closed -$7K – 11047
2022
Q2 		$7K Buy
2,282
+666
+41% +$3.15K ﹤0.01% 8548
2022
Q1 		$14K Sell
1,616
-2,822
-64% -$26.3K ﹤0.01% 7970
2021
Q4 		$47K Sell
4,438
-9,435
-68% -$141K ﹤0.01% 6969
2021
Q3 		$249K Buy
+13,873
New +$287K ﹤0.01% 5169

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

UBS Group's CLYM Position: Q1 2026 in Review

UBS Group increased its Climb Bio (CLYM) stake by 21% in Q1 2026, buying an estimated $84.4K and bringing the position to 85,945 shares worth $589K. The position accounts for ﹤0.01% of the portfolio, ranked #5969.

UBS Group first reported a position in CLYM in Q3 2021 and has held it in 14 quarters since. The position peaked at $815K in Q3 2025. 80 funds tracked by Wall St. Rank hold CLYM as of Q1 2026.

  • UBS Group held 85,945 shares of Climb Bio worth $589K as of Q1 2026.
  • UBS Group bought 14,622 Climb Bio shares in Q1 2026, an estimated $84.4K.
  • Climb Bio made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #5969 holding.
  • UBS Group first reported a position in Climb Bio in Q3 2021 and has held it in 14 quarters since.
  • UBS Group's Climb Bio position peaked at $815K in Q3 2025.
  • 80 funds tracked by Wall St. Rank held Climb Bio as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.